SCHEMBL5055155

SCHEMBL5055155

CC(C)(C)c1cc(NC(=O)Nc2cccc(-c3cccc4c3CNC4=O)c2)n(-c2ccc3c(c2)CCNC3)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.49
KDR P35968 8/20 0.47
MAPK13 O15264 10/20 0.46
MAPK12 P53778 10/20 0.46
MAPK11 Q15759 10/20 0.46
MAPK14 Q16539 10/20 0.46
ROCK2 O75116 2/20 0.46
RET P07949 2/20 0.46
FLT1 P17948 2/20 0.46
EPHA2 P29317 2/20 0.46
FLT4 P35916 2/20 0.46
FLT3 P36888 2/20 0.46
AURKB Q96GD4 2/20 0.46
PLK4 O00444 1/20 0.46
AURKA O14965 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
CSF1R P07333 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082144 0.93 KDR (0.53) ABL1KDRMAPK13MAPK12MAPK11
Hydrochloric Acid SCHEMBL2082034 0.93 KDR (0.53) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5060551 0.90 KDR (0.53) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5054979 0.89 ABL1 (0.60) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5052208 0.89 ABL1 (0.55) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5056378 0.88 KDR (0.47) KDRMAPK13MAPK12MAPK11MAPK14
SCHEMBL5059990 0.86 ABL1 (0.57) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5056305 0.86 ABL1 (0.52) ABL1KDRMAPK13MAPK12MAPK11
SCHEMBL5056467 0.85 BRAF (0.56) KDRMAPK13MAPK12MAPK11MAPK14
SCHEMBL5056379 0.85 KDR (0.55) KDRMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 ABL1 20/4885KDR 41/4885MAPK13 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.